Today: 23 May 2026
Can Vanguard’s VTI ETF Really Turn $1,000 Into $1.39 Million? Why the Total Stock Market Fund Is Back in Focus

Can Vanguard’s VTI ETF Really Turn $1,000 Into $1.39 Million? Why the Total Stock Market Fund Is Back in Focus

NEW YORK, March 23, 2026, 11:19 EDT

Vanguard’s Total Stock Market ETF is back in the headlines after fresh weekend takes from Motley Fool and Australia’s The Bull. The pitch hasn’t changed: Both outlets say the low-fee fund still works as a straightforward path to long-term exposure across the entire U.S. market. On Saturday, a Motley Fool article crunched the numbers—if you started with $1,000 and added $200 every month, sticking to VTI’s average returns over the past ten years, you’d be looking at around $1.39 million after 30 years.

Timing’s key here: as of Feb. 28, VTI’s ETF share class had $586.3 billion under management and an ultra-low 0.03% expense ratio—making it one of the cheapest ways to get exposure to broad U.S. equities. Monday, late morning in New York, VTI was up $7.35 at $327.69 after Wall Street bounced back on news that President Donald Trump delayed strikes on Iranian power infrastructure.

Even with the rebound, the bullish argument isn’t about what’s happening right now. Year to date through March 20, Vanguard data puts VTI’s drop at 4.45%. So when you see that “millionaire math” floating around this weekend, remember: it’s based on the power of compounding over the long haul, not on today’s return numbers. Vanguard

VTI, an exchange-traded fund, trades like a regular stock while bundling shares from over 3,500 U.S. companies. It follows the CRSP US Total Market Index. The fund’s market-cap weighting pushes giants like Nvidia, Apple, Microsoft, Alphabet, and Amazon to dominate its holdings.

Motley Fool’s Anthony Di Pizio argued March 14 that VTI’s wide diversification delivers “great for producing steady returns with low volatility.” But he flagged a drawback: that same broad exposure can cause VTI to lag behind the more concentrated S&P 500 and Nasdaq-100 over extended periods. Yahoo Finance picked up his take via syndication. The Motley Fool

Patrick Sanders, an analyst with Motley Fool, put it this way on March 21: “all it takes is time and consistency.” Taking VTI’s average annual return of about 15% over the past decade, he ran the numbers—$1,000 to start, add $200 every month, and the potential outcome: after 10 years, that could be around $58,100; at the 20-year mark, just over $300,000; stretch it to 30 years, you’re looking at nearly $1.39 million. The Motley Fool

Australian investors face more than just the U.S. equity question, The Bull noted—they also have to pick the right wrapper. The latest guide flagged VTI on NYSE Arca as a direct route, or the ASX-listed VTS for similar exposure. Another pick: iShares’ IVV, which gives local buyers S&P 500 access in a straightforward package.

This is where the competition really comes into focus. VTI stretches past just the 500 largest U.S. names, capturing mid- and small-caps too. IVV, on the other hand, sticks with the big players. According to The Bull, that edge gives VTI or VTS the nod as the more straightforward total-market pick—though IVV could still be simpler for Australians to own.

But there are drawbacks. The Bull pointed out the full U.S. dollar exposure, extra tax paperwork, more admin, and estate-planning hurdles for Australians holding a U.S.-domiciled fund. Di Pizio also noted that VTI tends to underperform when just a small group of mega-cap tech stocks are driving most of the gains. U.S. investors aren’t immune either—the fund stays completely exposed if equity markets slide.

Chris Larkin, managing director of trading and investing at E*TRADE from Morgan Stanley, flagged that Monday’s rally hinges on real progress with geopolitics, emphasizing the market remains “headline-driven.” VTI buyers, he noted, are still facing a market where long-term compounding is jostling against abrupt, sometimes violent, short-term moves. Reuters

Stock Market Today

  • UBS Boosts Jazz Pharma Stock Price Target to $307 Ahead of FDA Decision
    May 23, 2026, 2:29 PM EDT. UBS upgraded Jazz Pharmaceuticals (JAZZ) stock from neutral to buy, raising its price target by 63% to $307 from $188. This surge exceeds the prior consensus of $242 and follows strong Q1 results, with revenue up 19% year-over-year and oncology portfolio growth of 45%. The move anticipates FDA approval on August 25 of Zanidatamab (Ziihera) for HER2-positive gastroesophageal cancer, expected to generate peak sales of $3.1 billion. UBS projects 10% revenue and 11% earnings growth from 2026-2030, versus consensus of around 7% and 6%, and supports a valuation multiple increase from 7x to 10x earnings, reflecting confidence in sustainable growth. Key risks include FDA delays, slower oncology sales ramp, and underperformance of core franchises like Xywav and Epidiolex.

Latest articles

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

23 May 2026
AbbVie shares closed Friday at $215.70, up 0.56%, gaining 2.5% for the week. The company reported a positive European panel recommendation for MAVIRET in acute hepatitis C and released new oncology data ahead of the ASCO meeting. U.S. markets are closed Monday for Memorial Day, with trading set to resume Tuesday.
Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

23 May 2026
Coherent Corp. shares closed at $377.57 Friday, down 0.1% for the day and 1.3% below last week, underperforming the S&P 500 and Nasdaq ahead of the Memorial Day market closure. The company reported fiscal Q3 revenue of $1.81 billion, up 21% year-over-year, with strong demand in datacenter and communications. Nvidia invested $2 billion in March and signed a multi-year optics agreement. Coherent trades at 179 times trailing earnings.
Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

23 May 2026
Intuit will cut about 3,000 jobs, or 17% of its workforce, and close offices in Reno and Woodland Hills as it restructures to focus on artificial intelligence. The company expects $300 million to $340 million in charges, mostly in the fiscal fourth quarter. Intuit raised full-year revenue guidance but lowered its TurboTax outlook, citing pressure from low-cost AI tools. Shares last traded at $319.94 after a volatile week.
Boeing Stock Debate Widens as Bullish $290 Target Meets Debt, Certification Risk
Previous Story

Boeing Stock Debate Widens as Bullish $290 Target Meets Debt, Certification Risk

Oklo Stock Rises After First NRC License, but Cash Burn Keeps Pressure On
Next Story

Oklo Stock Rises After First NRC License, but Cash Burn Keeps Pressure On

Go toTop